Changes in Beneficial Ownership · 4
Xeris Biopharma Holdings, Inc.
XERSNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1790974451.xml
Filing details
- Report period
- 2026-10-01
- Issuer
- Xeris Biopharma Holdings, Inc.
- Issuer CIK
- 0001867096
- Trading symbol
- XERS
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Hecht Beth
- Reporting owner CIK
- 0001652410
- Relationship
- Officer
- Officer title
- See Remarks
- Address
- C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL, 60607
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-01 | S · Form 4[F1] | 16,666 | D | 9.4079[F2] | 1,111,130 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Footnotes
- F1
- The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.↩ 1
- F2
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.180 to $9.680, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1
Remarks
Chief Legal Officer and Corporate Secretary
Signature 1
- Signed
- /s/ Beth Hecht
- Date
- 2026-10-02